IP Library Granted Patent US 10,125,189
Granted Patent B2
US 10,125,189 · App. 14/855,686 · Granted Nov 13, 2018

Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,125,189
App. No.
14/855,686
Granted
Nov 13, 2018
Kind
B2
Abstract

The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.

Claims (29)

1. A method for preparing a concentrated immunoglobulin G (IgG) composition, comprising:

(A) concentrating IgG in a solution to a first concentration of from 2% to 10% (w/v) by ultrafiltration using a first ultra-/diafiltration system comprising a first ultrafiltration membrane having a first nominal molecular weight cut off and a first surface area;

(B) diafiltering the IgG in the solution against a diafiltration buffer using the first ultra-/diafiltration system comprising the first ultrafiltration membrane; and

(C) concentrating the IgG in the solution to a second concentration of greater than 20% (w/v) by ultrafiltration using a second ultra-/diafiltration system comprising a second ultrafiltration membrane having a second nominal molecular weight cut off and a second surface area, wherein the second surface area of the second ultrafiltration membrane is less than the first surface area of the first ultrafiltration membrane.

2. The method of claim 1 , wherein the surface area of the second ultrafiltration membrane is no more than a tenth of the surface area of the first ultrafiltration membrane.

3. The method of claim 1 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 100 kDa or less.

4. The method of claim 2 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 100 kDa or less.

5. The method of claim 1 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 50 kDa or less.

6. The method of claim 2 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are separately 50 kDa or less.

7. The method of claim 1 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 50 kDa.

8. The method of claim 2 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 50 kDa.

9. The method of claim 1 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 30 kDa.

10. The method of claim 2 , wherein the first nominal molecular weight cut off of the first ultrafiltration membrane and the second nominal molecular weight cut off of the second ultrafiltration membrane are both 30 kDa.

11. The method of claim 1 , wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2±0.1.

12. The method of claim 2 , wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2±0.1.

13. The method of claim 8 , wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2±0.1.

14. The method of claim 10 , wherein the diafiltration buffer comprises from 0.2 M to 0.3 M glycine and a pH of 4.2±0.1.

15. The method of claim 1 , further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system:

(D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and

(E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane.

16. The method of claim 2 , further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system:

(D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and

(E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane.

17. The method of claim 8 , further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system:

(D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and

(E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane.

18. The method of claim 10 , further comprising, after concentrating the IgG in the solution using the first ultra-/diafiltration system:

(D) washing the first ultrafiltration membrane by re-circulating a post-wash buffer through the first ultra-/diafiltration system, thereby recovering IgG lost from the solution; and

(E) concentrating the recovered IgG using the second ultra-/diafiltration system comprising the second ultrafiltration membrane.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: TESCHNER, WOLFGANG; BUTTERWECK, HARALD ARNO; PLJEVLJAKOVIC, AZRA; BAUER, THERESA FRIEDERIKE; KOELBL, BERNHARD; SCHWARZ, HANS-PETER; NIKOLIC, NEBOJSA; POELSLER, GERHARD; KINDERMANN, JOHANNA
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE SA
Reel/Frame 044813/0469 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 045231/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 045231/0401 →